1. Therapeutic Goods Administration (Australian Government). 2023. Change to classification of psilocybin and MDMA to enable prescribing by authorised psychiatrists. https://www.tga.gov.au/news/media-releases/change-classification-psilocybin-and-mdma-enable-prescribing-authorised-psychiatrists Accessed 4 June 2023.
2. Health Canada. Notice to stakeholders: Requests to the Special Access Program (SAP) involving psychedelic-assisted psychotherapy. 2023. https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/announcements/requests-special-access-program-psychedelic-assisted-psychotherapy.html Accessed 4 June 2023.
3. Delay P, Lemperiere Q. Effet therapeutique de la psilocybine sur une nevrose convulsive. Annales Medico-Psychologiques: Revue Psychiatrique. Masson & CLE, editors. Paris: Libraires De L'Academie de Medicine; 1959. p. 509–15.
4. Mangini M. Treatment of alcoholism using psychedelic drugs: a review of the program of research. J Psychoact Drugs. 1998;30(Dec):381–418.
5. Rucker JJ, Iliff J, Nutt DJ. Psychiatry & the psychedelic drugs. Past, present & future. Neuropharmacology 2018;142:200–18.